ANCA Testing Demystified: When to Order, How to Interpret, and When to Leave It Alone

 

ANCA Testing Demystified: When to Order, How to Interpret, and When to Leave It Alone

Vasculitis serologies are powerful—but ordering them for the wrong reasons creates more problems than it solves.

ANCA testing is one of the most misused lab panels in primary care. It gets ordered for vague joint pain, nonspecific rashes, or an elevated ESR—and then a low-positive p-ANCA comes back, everyone panics, and the patient gets a workup they never needed. Meanwhile, the patient with bloody nasal crusting and rising creatinine who actually has vasculitis sometimes gets missed because nobody thought to test.

Let's fix that.

What Is ANCA, and What Are We Actually Testing?

ANCA stands for Anti-Neutrophil Cytoplasmic Antibodies. These are autoantibodies directed against proteins inside neutrophils, and they're the serologic hallmark of a group of rare, serious, small-vessel vasculitides collectively called ANCA-associated vasculitis (AAV).

AAV includes three diseases:

• Granulomatosis with polyangiitis (GPA) — formerly Wegener's. Affects the upper and lower respiratory tract and kidneys. Often presents with chronic sinusitis, nasal crusting/bleeding, pulmonary nodules, and glomerulonephritis.
• Microscopic polyangiitis (MPA) — predominantly affects kidneys and lungs. Often presents as rapidly progressive glomerulonephritis and/or alveolar hemorrhage.
• Eosinophilic granulomatosis with polyangiitis (EGPA) — formerly Churg-Strauss. Late-onset asthma, eosinophilia, and multisystem vasculitis. ANCA-positive in only about 30–40% of cases.

The Two Testing Methods: IIF vs. Antigen-Specific Assays

There are two layers to ANCA testing, and understanding both is key to interpreting results correctly:

Indirect Immunofluorescence (IIF) — The Pattern

The original method. Patient serum is applied to ethanol-fixed neutrophils, and the fluorescence pattern is read under a microscope:

• c-ANCA (cytoplasmic pattern) — diffuse granular staining of the cytoplasm. In the context of vasculitis, this is almost always caused by antibodies against proteinase 3 (PR3).
• p-ANCA (perinuclear pattern) — staining concentrated around the nucleus. In vasculitis, this is usually caused by antibodies against myeloperoxidase (MPO).
• Atypical ANCA — positive IIF but negative for both PR3 and MPO on specific assays. This pattern is common in IBD, autoimmune liver disease, and other non-vasculitic conditions. It is not specific for AAV.

Antigen-Specific Assays (ELISA/CLIA) — The Target

These directly measure antibodies against the two key proteins:

• PR3-ANCA (anti-proteinase 3) — the antibody behind most c-ANCA patterns
• MPO-ANCA (anti-myeloperoxidase) — the antibody behind most p-ANCA patterns

Critical Update

Current international guidelines now recommend that antigen-specific testing (PR3 and MPO) can be used as the primary screening method, without requiring IIF first. Many reference labs now default to this approach. The key point: a positive PR3-ANCA or MPO-ANCA in the right clinical context is sufficient to support an AAV diagnosis. IIF alone, particularly an isolated p-ANCA without a positive MPO, is often clinically meaningless for vasculitis.

PR3-ANCA vs. MPO-ANCA: They're Not the Same Disease

Increasingly, experts advocate classifying patients by ANCA serotype rather than just the traditional disease names. The antibody type predicts behavior better than the clinical label alone:

PR3-ANCA (c-ANCA)

• Strongly associated with GPA
• ENT involvement: bloody nasal crusting, sinusitis, saddle-nose deformity, subglottic stenosis
• Pulmonary: nodules, cavitary lesions, alveolar hemorrhage
• Renal: glomerulonephritis
• Higher relapse rate
• More organs typically involved
• More common in Northern European/White populations
• ~75% of GPA patients are PR3-positive

MPO-ANCA (p-ANCA)

• Strongly associated with MPA
• Renal-dominant: often presents as rapidly progressive GN
• Pulmonary: interstitial lung disease, fibrosis, alveolar hemorrhage
• Less ENT involvement
• Lower relapse rate (but relapses still occur)
• More common in Asian and Southern European populations
• ~70% of MPA patients are MPO-positive
• Also seen in ~40% of EGPA

The Pitfalls: Where Primary Care Gets Into Trouble

1. Ordering ANCA for Nonspecific Symptoms

This is pitfall number one, and it's rampant. ANCA gets ordered for fatigue, myalgias, elevated ESR, nonspecific rash, or vague joint pain—and then a low-positive p-ANCA comes back. This almost never means vasculitis.

Remember: p-ANCA (by IIF) without a positive MPO-ANCA is found in a long list of non-vasculitic conditions:

• Inflammatory bowel disease (Crohn's and UC)
• Autoimmune hepatitis and primary sclerosing cholangitis
• Rheumatoid arthritis
• SLE (15–20% of lupus patients can be ANCA-positive)
• Infections
• Various medications

Rule of Thumb

If you don't have a specific clinical reason to suspect small-vessel vasculitis, don't order ANCA. A low pretest probability + a low-positive ANCA = a false positive that generates anxiety, unnecessary referrals, and potentially harmful biopsies. ANCA testing should be driven by clinical suspicion, not used as a screening tool for nonspecific inflammation.

2. Ignoring the 5–10% Who Are ANCA-Negative

Here's the flip side: approximately 5–10% of patients with biopsy-proven GPA or MPA are ANCA-negative. Up to 70% of EGPA patients are seronegative. A negative ANCA does not rule out vasculitis if the clinical picture is compelling. If you have a patient with rapidly progressive glomerulonephritis, pulmonary-renal syndrome, or destructive upper airway disease, they need a rheumatology or nephrology referral regardless of the ANCA result.

3. Confusing "Atypical p-ANCA" with AAV

An atypical ANCA pattern—positive on IIF but negative for both PR3 and MPO—is not associated with ANCA-associated vasculitis. It's most commonly seen in IBD and autoimmune liver diseases. Ordering the antigen-specific assays (PR3 and MPO) is what distinguishes a clinically meaningful result from noise.

4. Drug-Induced ANCA Vasculitis

Several medications can trigger ANCA production and even clinical vasculitis:

• Propylthiouracil (PTU) — the most well-known offender; can cause MPO-ANCA-positive vasculitis with glomerulonephritis and alveolar hemorrhage
• Hydralazine — another common culprit, especially with long-term use
• Minocycline
• Levamisole-adulterated cocaine — causes dual PR3 + MPO positivity with skin lesions and arthralgias
• Anti-TNF agents (infliximab, etanercept) — rare but reported

Clinical Pearl

Always take a thorough medication and substance use history before attributing ANCA positivity to primary vasculitis. Drug-induced ANCA vasculitis often resolves after stopping the offending agent, though severe cases may still require immunosuppression for induction.

5. Using ANCA to Monitor Disease Activity (It's Complicated)

This is a nuanced area. Rising PR3-ANCA levels have a moderately useful association with relapse in GPA—but it's not reliable enough to change treatment based on serology alone. For MPO-ANCA, the data is even less clear. Current practice: serial ANCA levels can be one piece of the monitoring puzzle, but treatment decisions should be based on clinical disease activity, not solely on rising titers.

6. ANCA Can Be Positive After COVID-19 Vaccination (Rarely)

Case reports have described new-onset AAV following SARS-CoV-2 vaccination, including rare cases of dual PR3/MPO positivity. This is exceedingly rare relative to the hundreds of millions of doses administered, but it's worth noting if you see a patient develop vasculitis symptoms in temporal association with vaccination.

When Should NPs Order ANCA?

Order ANCA (PR3 and MPO) When You See

• Rapidly progressive glomerulonephritis (rising creatinine + active urine sediment with RBCs/casts)
• Pulmonary-renal syndrome (GN + alveolar hemorrhage/hemoptysis)
• Chronic destructive sinusitis with bloody/crusting nasal discharge not responding to standard treatment
• Pulmonary nodules or cavitary lesions without clear infectious etiology
• Unexplained alveolar hemorrhage (hemoptysis + bilateral infiltrates)
• Palpable purpura or cutaneous vasculitis
• Mononeuritis multiplex (asymmetric peripheral nerve deficits)
• New-onset severe asthma + eosinophilia + multisystem symptoms (think EGPA)
• Scleritis or orbital pseudotumor
• Subglottic stenosis (especially in a younger patient)

Do NOT Order ANCA For

• Nonspecific fatigue or myalgias
• Isolated elevated ESR or CRP without organ-specific findings
• Generalized arthralgias without evidence of vasculitis
• Routine ANA workup add-on (ANCA and ANA are completely different pathways)
• Nonspecific rashes or urticaria
• "Just to be thorough" — this is how false positives are born

Quick-Reference Table

Pattern/Antibody	Primary Association	Key Pitfall
c-ANCA / PR3-ANCA	GPA (Wegener's); ~90% concordance between c-ANCA and PR3	Higher relapse rate; rising titers may precede flare but aren't reliable enough alone to change therapy
p-ANCA / MPO-ANCA	MPA, EGPA, drug-induced vasculitis	p-ANCA pattern on IIF WITHOUT positive MPO is usually IBD, autoimmune liver disease, or other non-vasculitic cause
Atypical ANCA	IBD (especially UC), autoimmune hepatitis, PSC	NOT associated with AAV. Don't refer for vasculitis workup based on this alone.
ANCA-negative AAV	5–10% of GPA/MPA; up to 70% of EGPA	Negative ANCA does NOT exclude vasculitis. Biopsy may still be needed if clinical suspicion is high.
Drug-induced ANCA	PTU, hydralazine, minocycline, levamisole/cocaine	Usually MPO-ANCA positive; often resolves after stopping the offending drug. Always take a med/substance history.

The Diagnostic Workflow for Primary Care

1. Clinical suspicion first. Don't order ANCA without organ-specific signs pointing toward small-vessel vasculitis.
2. Order PR3-ANCA and MPO-ANCA (antigen-specific assays). Some labs will reflex to IIF if positive; others run all three simultaneously.
3. Get a urinalysis with microscopy at the same time. Active sediment (dysmorphic RBCs, RBC casts, proteinuria) in the setting of positive ANCA is an emergency.
4. Check CRP, ESR, CBC, BMP (creatinine!), and a chest X-ray if pulmonary symptoms are present.
5. Refer urgently. AAV can be life-threatening. If you have a positive PR3 or MPO with compatible clinical findings, this is a same-week (or same-day) referral to rheumatology or nephrology. Do not wait for the specialist appointment to recheck labs.
6. If ANCA is positive but the clinical picture doesn't fit (no organ involvement, no active sediment, no pulmonary findings), don't panic. Consider the pretest probability and alternative explanations (medications, IBD, other autoimmune disease). Refer for evaluation but communicate clearly that the clinical question is "is this a real positive?"

Bottom Line

ANCA testing is powerful but only when it's ordered for the right reasons. The diseases it helps diagnose—GPA, MPA, EGPA—are rare, aggressive, and treatable, but they require a high index of suspicion and a disciplined approach to testing. A positive ANCA in the right clinical context can be lifesaving. A positive ANCA in the wrong context is just noise that generates expensive, anxiety-provoking workups for conditions the patient doesn't have.

Know when to order it. Know what the patterns mean. And know when to leave it alone.

Stay sharp out there.